Decentralized trials

As the adoption of real-world evidence (RWE) in healthcare continues to grow, and with the FDA embracing these trials more and more, researchers have come to appreciate the significance of establishing uniform approaches for evaluating and analyzing real-world data (RWD).

Castor announces the appointment of Brad Hightower, a leading clinical trials executive, to its advisory board.

As we kick-off 2023 with a refreshed mindset, we take inventory of what is important and focus on our goal to continuously make sure that we are maximizing the impact of data on the global disease burden with more inclusive, patient-friendly trials.

Martijn Kersloot, PhD, Product Owner at Castor, gives an introduction into the FAIR Data Principles and highlights why collecting machine-readable data is crucial

Learn best practices on RWE, Castor’s offerings for collecting RWD, and 3 different RWE case studies from Castor clients

Learn key compliance requirements, data collection tips, and important dates for the EU Medical Device Regulation in this white paper.

There are ongoing debates about whether or not our industry should call all decentralized ones digital trials; however, most of us need help understanding the fundamental step to successfully operate both types of trials, which is effective data monitoring.

Learn why having a good user interface is crucial for enrolling and retaining patients in a decentralized clinical trial

Watch this webinar from ixlayer and Castor to find out where some of the hesitancy in running a decentralized clinical trial lies, and how to address these concerns to run a DCT effectively

Listen to our CEO & Founder Derk Arts share his thoughts about why remote-first is the only way forward and what we can lean into right now to achieve it.